Clinical Trials
37 trialsA Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
Boryung Pharmaceutical Co., Ltd
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
Dizal Pharmaceuticals
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Daiichi Sankyo
LuminICE-203
Affimed GmbH
AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
Dizal Pharmaceuticals
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Great Novel Therapeutics Biotech & Medicals Corporation
PRIMO
SecuraBio
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
Evopoint Biosciences Inc.
REDIRECT
Affimed GmbH
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
BeiGene
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
HUYABIO International, LLC.
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
AstraZeneca
PTCL
Kura Oncology, Inc.
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Kyowa Kirin Co., Ltd.
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen Inc.
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Kyowa Kirin Co., Ltd.
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Solasia Pharma K.K.
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Seagen Inc.
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
Karyopharm Therapeutics Inc
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
Rhizen Pharmaceuticals SA
PTCL
Spectrum Pharmaceuticals, Inc
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Eisai Inc.
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)
Genor Biopharma Co., Ltd.
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma(PTCL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).
Shandong New Time Pharmaceutical Co., LTD
A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma
Nanjing Sanhome Pharmaceutical, Co., Ltd.
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Eisai Inc.
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Celgene
PROPEL
Acrotech Biopharma Inc.
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
Acrotech Biopharma Inc.
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
CerRx, Inc.
Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
Nanjing NingQi Medicine Science and Technology Co., Ltd.
PXD101-CLN-6
Valerio Therapeutics
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Alaunos Therapeutics